NeuroOne Medical Technologies Corporation (NMTC)
| Previous Close | 0.8290 |
| Open | 0.8600 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.8100 - 0.8600 |
| 52 Week Range | 0.6020 - 2.0000 |
| Volume | |
| Avg. Volume | 79,040 |
| Market Cap | 25.574M |
| Beta (5Y Monthly) | 0.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4800 |
| Earnings Date | Dec 12, 2024 - Dec 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireNeuroOne® Announces Breakthrough Case Completed with OneRF™ Ablation System at the University Hospitals in Cleveland
Forty-four ablations performed successfully in one patient Patient currently reportedly seizure free with improvements in mood and memory EDEN PRAIRIE, Minn., Sept. 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the OneRF Ablation System was recently used in a breakthroug
- GlobeNewswire
NeuroOne® to Present at the H.C. Wainwright 26th Annual Global Investment Conference
EDEN PRAIRIE, Minn., Sept. 05, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its upcoming virtual investor presentation at the H.C. Wainwright 26th Annual Global Investment Conference being held in-person and virtually on September 9-11, 2024. The Company’s virtual presentation b
- GlobeNewswire
NeuroOne® Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
EDEN PRAIRIE, Minn., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the third quarter fiscal year 2024 ended June 30, 2024. Third Quarter Fiscal Year 2024 and Recent Business Updates Financial Highlights: Product revenue of $826,000 in Q3 2024, c
